U.S. stock night trading anomaly: Quoin Pharmaceuticals rose 8.89% in night trading, with active capital flow attracting market attention

U.S. Stock Night Market Movements Quoin Pharmaceuticals rose 8.89% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks with High Trading Volume in the Industry Recursion fell 2.73% in the night market. Based on recent key news: On December 8, Recursion Pharmaceuticals announced clinical trial data for REC-4881, showing a 43% reduction in polyp burden in patients with hereditary adenomatous polyposis. This positive result drove the stock price up about 3%. Source: GlobeNewswire On December 8, Recursion Pharmaceuticals' stock price rose 6.2% in pre-market trading due to its experimental oral drug REC-4881 showing significant efficacy in early to mid-stage trials. The company plans to expand the research scope, which boosted the stock price. Source: Reuters On December 8, Recursion Pharmaceuticals' CEO stated that the company is adopting AI technology for drug discovery and safety testing, expecting to significantly shorten time and costs in the coming years. This technological advancement has enhanced market confidence in the company. Source: Reuters The biotechnology industry has been active recently, with significant capital inflows. Moderna fell 1.17% in the night market. Based on recent key news: On December 9, Moderna executive Klinger Shannon Thyme submitted Form 4, disclosing changes in stock holdings. This move may raise market attention on the company's insider trading, leading to stock price fluctuations. According to SEC filings, Klinger exercised 47,190 stock options on December 5 and returned 22,817 shares to cover exercise costs and tax liabilities. Source: Washington Service On December 11, Moderna reached a collaboration agreement with Nanexa involving up to $500 million in development and commercial milestone payments. This agreement may enhance Moderna's product development capabilities and boost market confidence. Source: Reuters On December 10, U.S. health regulators are investigating potential death incidents related to the COVID-19 vaccine. Although Moderna reiterated the safety of its vaccine, market concerns about vaccine safety may affect the stock price. Source: Reuters The competition in the mRNA vaccine market is intensifying, with increased regulatory risks. Biodexa Pharmaceuticals fell 5.65% in the night market, with a trading volume of $56,000, and no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation